Objective To introduce the surgical treatment experiences of upper gastric cancer in our department in recent 10 years for improving its therapeutic level. Methods 94 patients with upper gastric cancer underwent proximal subtotal gastrectomy or total incision plus the left seventh to ninth ribs resection. Results One case developed a fistula at the anastomosis, 3 cases had residual tumor cells at the esophageal margin, and 8 cases developed pttlmonary infections. No one developed costal chondritis or hemopneumothorax followed by pleura injury. Conclusions Operations through mid-abdominal incision on patients with upper gastric cancers, which provide a well exposure, less injury and pain, and are applicable to those whose esophageal invasion is under 1 cm of length.

Advanced schistosomiasis,encompassing a wide range of pathologic entities and multi-complications,poses a se-rious threat on the patients'health. Through comprehensive analysis and evaluation on related aspects regarding clinical classifi-cation,main methods of auxiliary examination and treatment(including types of surgical procedure)of advanced schistosomia-sis,we think that the individual based multidisciplinary comprehensive treatment according to varying conditions of patients is the most optimal treatment mode of advanced schistosomiasis. It is further proposed that multidisciplinary collaborative diagnosis and treatment system should be undoubtedly established,multidisciplinary case discussions be regularly organized,and treat-ment expert teams be stably formed,in order to significantly improve the level of diagnosis and treatment of advanced schistoso-miasis,so as to reduce the misdiagnosis and improve the therapeutic effect in advanced schistosomiasis control.

OBJECTIVE:To optimize the inclusion technology of Eugenol-β-cyclodextrin (β-CD) inclusion complex,and to identify and characterize it. METHODS:With the molar ratio of eugenol to β-CD,inclusion temperature and inclusion time as fac-tors,using the yield of inclusion compounds as index,the inclusion technology was optimized by orthogonal test. The formation of inclusion compound was identified by the spectra change of FT-IR,XRD and 1H NMR. Its structure was characterized by 1H RO-ESY NMR. RESULTS:The optimized inclusion conditions were that the molar ratio of eugenol to β-CD was 1.0:1;inclusion tem-perature was 60 ℃;inclusion time was 2.0 h. And the yield of inclusion compound was 73.86%(RSD=0.17%,n=3). 1H NMR results ofβ-CD and its inclusion complex indicated that the optimum qualitative ratio of the inclusion complex was 1.0:1. The inter-molecular interaction between eugenol and β-CD was confirmed by the spectrum analysis of FT-IR and XRD. 1H ROESY NMR re-sults indicated the structure of inclusion complex mainly was that the phenyl of eugenol was in the cavity of β-CD,the vinyl was outside. CONCLUSIONS:The inclusion technology is reasonable and feasible,and can be used for the inclusion of eugenol andβ-CD. The formation of inclusion compound is confirmed by the spectrum analysis.

Background and purpose:There are few studies referring to population-based cancer survival of bladder cancer for more than forty years in China. This paper was to offer basis for assessing long-term survival trends of bladder cancer and the prognosis of this cancer through analysis of the survival rates based on cancer report documents from 1972 to 2011 in Qidong.Methods:The deadline of the last follow-up for survival status of the 1 619 registered cases was Apr. 2012. Cumulative observed survival rate (OS) and relative survival rate (RS) were calculated using Hakulinen’s method performed by the SURV3.01 Software which is developed by Finnish Cancer Registry.Results:The one-, three-, five-, ten-, fifteen-, twenty-, and thirty-year OS rates were 59.91%, 43.49%, 35.98%, 26.91%, 21.30%, 18.37% and 12.24%; and the one-, three-, five-, ten-, fifteen-, twenty-, and thirty-year RS rates were 64.07%, 53.02%, 50.06%, 52.42%, 59.59%, 76.39% and 115.75%, respectively. For males, these OS rates were 60.84%, 43.91%, 36.95%, 27.31%, 21.49%, 18.29% and 12.59%, and RS rates were 65.23%, 53.95%, 52.02%, 54.57%, 62.59%, 79.12% and 117.07%, respectively; For females, these OS rates were 56.61%, 42.03%, 32.44%, 25.65%, 20.78%, 18.80% and 0%, and RS rates, 59.99%, 49.91%, 43.37%, 45.86%, 51.21%, 69.02% and 0%, respectively. There were no statistical differences couldbe found between both sexes (P=0.256). Five-year RS rates of age groups 15-34, 35-44, 45-54, 55-64, 65-74, and more than 75 were 49.10%, 67.53%, 62.77%, 53.92%, 46.59% and 39.85%, and 10-year RS rates, 49.79%, 61.23%, 52.99%, 48.21%, 54.94% and 51.21%, respectively. Remarkable improvement could be seen for the five-, ten-, and fifteen-year RS rates in this setting since 1980’s.Conclusion:The survival outcome from Qidong registered cases with bladder cancer shows gradual progress during the past 2 decades. Early detection and improvement of therapies may be the factors affecting the prognosis of bladder cancer. Although the disparities in survival rates between Qidong and the developed countries are getting narrower, potential for survival improvement still exists.

Objective To analyze the survival rates of patients with non-Hodgkin lymphoma (NHL) in Qidong from 1972 to 2011,in order to provide the basis for the prognosis assessment and the control of this cancer.Methods A total of 1 472 registered NHL cases were followed up to April 30, 2012.Cumulative observed survival (OS) rate and relative survival (RS) rate were calculated using Hakulinen method performed by the SURV 3.01 software developed at the Finnish Cancer Registry.Results The 1-, 3-, 5-, 10-, 20-and 30-year OS rates were 32.48 ％, 19.30 ％, 15.78 ％, 12.76 ％, 9.54 ％ and 7.63 ％, and the RS rates were 33.49 ％, 21.18 ％, 18.46 ％, 17.79 ％, 19.37 ％ and 22.44 ％, respectively.The 1-, 3-, 5-, 10-, 20-and 30-year RS rates of males vs females had no statistically significant differences (x2 =3.32, P =0.767).The 5-year RS rates of age groups 0-14, 15-34, 35-44, 45-54, 55-64, 65-74, and ≥75 were 22.99 ％, 20.51％,18.42 ％, 20.96 ％, 18.72 ％, 17.32 ％, 10.60 ％, and the 10-year RS rates were 23.04 ％, 15.55 ％, 15.91％,16.36 ％, 18.59 ％, 19.70 ％, 20.93 ％, respectively.The age group 0-14 had the highest 5-and 10-year RS rates.Remarkable improvement could be seen in the 5-year RS rate from 7.76 ％ in 1973-1977 to 26.79 ％ in 2003-2007, and the 10-year OS rate from 6.63 ％ in 1973-1977 to 15.52 ％ in 1998-2002, respectively.Conclusions The outcome of NHL in Qidong has been improved gradually from 1972 to 2011, but the gaps of survival rates in NHL patients between China and the developed countries still exist.Research on the diagnosis and treatment of NHL should be further emphasized.

Objective Survival rates of pancreas cancer during the years 1972-2011,from a population-based cancer registry in Qidong,were analyzed in order to provide information for the prognosis assessment and control of this disease.Methods The deadline of the last follow-up for survival status of 3279 registered cases was April 30th,2012.DCO (death certificates only) cases were excluded,leaving 3272 cases for survival analysis.Cumulative observed survival rate (OS) and relative survival rate (RS) were calculated by the SURV3.01 software.Results The 1-,5-,10-,15-,20-,25-,and 30-year OSs were 12.69％,4.87％,3.76％,3.07％ 2.66％,1.94％ and 1.28％,respectively,and OSs in male were 12.39％,4.67％,3.41％,2.77％ 2.22％,1.35％,0.75％,and in female were 13.08％,5.12％,4.22％,3.45％,3.28％,3.00％ 2.40％.The 1-,5-,10-,15-,20-,25-,and 30-year RSs were 13.34％,6.30％,6.47％,7.34％ 9.27％,10.33％ and 10.65％,respectively;and the RSs in male were 13.06％,6.14％,6.06％ 6.91％,8.06％,7.44％,6.44％,and in female were 13.70％,6.47％,6.99％,7.88％,10.91％ 15.25％,19.12％.The 5-year OS rates at age groups of 15-34,35-44,45-54,55-64,65-74 and ＞75 were 17.81％,6.34％,8.32％,5.04％,3.75％ and 3.82％,respectively.The 5-year RSs were 17.97％,6.47％,8.65％,5.47％,4.68％ and 8.03％.Five-year OSs increased from 2.01％ in 1973-1977 to 5.11％ in 2003-2007.Conclusions The overall survival rate of pancreas cancer has increased during the past 40 years in Qidong,but the improvement is marginal.

There is no defined legislation on paternity testing in present China,thus the testing status quo is in a mess to some extent.Together with other unfavorable factors including the unstable marital status in modern society,increasing extramarital sexual behaviors and illegitimate children,and the ever-heated testing competition among testing institutes driven by the economic interests and so forth,the paternity testing is on a sharp rise these years,which leads to a increasing chaos in paternity testing field.Social ethical crisis is partially responsible for the current problem,thus related ethical issues to paternity testing are discussed in this article.

Objective: To investigate the survival rate and changing trends of kidney cancer patients in Qidong City from 1972 to 2016, so as to provide insights into kidney cancer control. Methods: Data pertaining to the incidence of kidney cancer in Qidong City from 1972 to 2016 were captured from the Qidong Municipal Cancer Registration System, and the final follow-up period was December 31, 2021. The observed survival rate, relative survival rate and standardized relative survival rate of kidney cancer were calculated to analyze the survival of kidney cancer, and the trends in survival were analyzed among kidney cancer patients from 1972 to 2016 using annual percent change (APC). Results: A total of 554 kidney cancer patients were reported in Qidong City from 1972 to 2016. The 1-, 3- and 5-year observed survival rates, relative survival rates and standardized relative survival rates were 62.27%, 50.54% and 44.04%; 64.31%, 55.71% and 51.93%; and 61.71%, 51.90%, and 51.68%, respectively. The 5-year observed survival rate, relative survival rate and standardized relative survival rate of kidney cancer appeared a tendency towards a rise in Qidong City from 1972 to 2016, with APC of 2.83% (t=4.303, P=0.004), 2.82% (t=3.978, P=0.005) and 3.96% (t=5.898, P=0.001), and the 5-year relative survival rate of kidney cancer was comparable between men and women (53.05% vs. 50.40%; χ2=4.872, P=0.676). There was an age-specific 5-year relative survival rate of kidney cancer (χ2=35.144, P<0.001), with the greatest among patients at ages of 35 to 44 years (64.49%) and the lowest at ages of 75 years and older (30.11%). Conclusion The 5-year survival rate of kidney cancer cases appeared a tendency towards a rise in Qidong City from 1972 to 2016. Further specific interventions, depending on age, are needed for management of kidney cancer.

Objective:To discuss the effect of sarcopenia (Sa) on the prognosis of transjugular intrahepatic portosystemic shunt (TIPS) in patients with portal hypertension (PHT).Methods:Totally 131 PHT patients treated with TIPS were retrospectively collected from August 2013 to December 2017 in the First Affiliated Hospital of USTC, and were divided into the Sa group [maximum transverse diameter of the psoas major muscle/height (TPMT/H) ≤16.8 mm/m, n=60] and the control group (TPMT/H>16.8 mm/m, n=71). The patients were followed up with a median time of 42 months. The Kaplan-Meier method was used to calculate the incidence of hepatic encephalopathy, recurrence rate of PHT-related complications and survival rate of PHT patients after TIPS, and the differences were compared by Log-rank test. Results:The incidences of hepatic encephalopathy within 6 months after TIPS and severe hepatic encephalopathy requiring hospitalization in the Sa group [36.7% (95%CI 24.5%-48.8%) and 15.0% (95%CI 6.0%-24.0%)] were higher than those of the control group [15.7% (95%CI 7.3%-24.1%) and 2.8% (95%CI 0-6.7%)], with statistically significant differences (χ2=7.843, 16.442, P=0.005, 0.001). The 5-year overall recurrence rate of PHT-related complications of the Sa group after TIPS [15.8% (95%CI 6.4%-25.2%)] was higher than that of the control group [5.7% (95%CI 0.2%-11.2%)], with a statistically significant difference (χ2=4.431, P =0.035. The 1, 3 and 5-year survival rates in the Sa group were 88.3% (95%CI 80.3%-96.3%), 86.7% (95%CI 78.1%-95.3%) and 77.8% (95%CI 65.1%-90.5%) respectively, which were all lower than those of the control group [97.2% (95%CI 93.3%-100%), 95.8% (95%CI 91.1%-100.0%) and 93.7% (95%CI 87.6%-99.87%) respectively], and the difference was statistically significant (χ2=5.055, P=0.025). Conclusion:Sa has a higher incidence in PHT patients, which can increase the incidence of hepatic encephalopathy and recurrence rate of PHT-related complications, and can decrease the survival rate in PHT patients after TIPS. Hence, the Sa is an indicator of the poor prognosis in PHT patients with TIPS.